FDA Rejects Moderna’s mRNA Flu Shot, Delays U.S. Rollout
FDA has refused to consider Moderna’s biologics license application for its quadrivalent mRNA-based influenza vaccine candidate, citing insufficient clinical data on immunogenicity and safety. The decision defers U.S. market entry and triggered a sharp share sell-off in early trading.
1. FDA Decision
The FDA refused to consider Moderna’s biologics license application for its quadrivalent mRNA-based influenza vaccine candidate, citing the need for additional clinical data on both immunogenicity and safety before initiating a formal review process.
2. Vaccine Candidate Profile
Moderna’s quadrivalent shot is designed to protect adults against four circulating influenza strains using the company’s messenger-RNA platform, positioning it as a key growth asset beyond its COVID-19 vaccine franchise.
3. Market Reaction
Moderna’s shares plunged sharply on the announcement, as investors reassessed the impact of a delayed U.S. launch on near-term revenue projections and overall pipeline valuation.
4. Path Forward
Moderna plans to work closely with regulators to clarify specific data requirements, conduct additional studies to bolster its submission and target approval for upcoming flu seasons.